Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs AUPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AUPH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

AUPH Overall Winner 6-Pillar Tally: NTLA 1 – 5 AUPH Matrix Metrics: NTLA 0 – 10 AUPH

As of Nov 16, 2026, Aurinia Pharmaceuticals Inc (AUPH) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas AUPH carries 55.7/100 (HOLD) at $15.47 (13.6x Forward P/E, 51.6% operating margin).

  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile AUPH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs AUPH
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $11.58 · SMA50: $11.86
AUPH NASDAQ Head-to-Head Winner
Aurinia Pharmaceuticals Inc
Pharmaceutical Preparations
$15.47
-1.62% 1D
Market Cap $2.1B
TTM Revenue $322M
Forward P/E 13.6x
Beta / 30D Vol 0.67β · 36% Vol
Unified Composite Score
55.7 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $16.62 · SMA50: $16.47

6-Pillar Scorecard Institutional Category Breakdown (NTLA 1 – 5 AUPH)

Columns: Metric · NTLA · AUPH
1. Valuation Multiples AUPH
Forward P/E N/M 13.6x
Trailing P/E N/M 7.0x
PEG Ratio N/M N/M
EV / Revenue 29.1x 6.7x
2. Growth & Scale AUPH
Revenue Growth (YoY) -48.0% +13.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $53M $322M
Market Cap $1.5B $2.1B
3. Profitability & Quality AUPH
Gross Margin N/A 75.7%
Operating Margin -826.0% 51.6%
Net Profit Margin 0.0% 97.7%
Return on Equity (ROE) -62.6% 61.4%
4. Balance Sheet & Cash Flow AUPH
Cash Generation (TTM) -$358M $177M
Cash Flow Margin N/A 55.0%
Net Cash / Leverage $74M Net Debt (0.38x D/E) $13M Net Debt (0.09x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AUPH
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 101.3% (78th %ile) 55.8% (48th %ile)
Put/Call OI Skew 0.42x (Call-Skewed) 0.12x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A 24.1% of Rev ($78M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (0) vs AUPH (10)
Institutional Metric NTLA AUPH Criterion Row Edge
Market Capitalization
Scale
$1.5B $2.1B Larger Scale AUPH
Trailing P/E Ratio
Valuation
N/M 7.0x Lower Multiple AUPH
Forward P/E Ratio
Valuation
N/M 13.6x Lower Multiple AUPH
Revenue Growth (YoY)
Growth
-48.0% +13.9% Higher Growth AUPH
Operating Margin (TTM)
Profitability
-826.0% 51.6% Higher Margin AUPH
Net Profit Margin
Profitability
0.0% 97.7% Higher Margin AUPH
Return on Equity (ROE)
Capital Efficiency
-62.6% 61.4% Higher ROE AUPH
52-Week Range Position
Momentum
20% ($8–$18) 34% ($14–$19) Stronger Trend AUPH
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 0.67β · 36% Vol Lower Realized Risk AUPH
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 55.7 / 100 (HOLD) Higher Composite AUPH
Trailing 12M Revenue (USD)
Operating Scale
$53M $322M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 75.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · 6.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) $177M ($13M Net Debt (0.09x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AUPH +6.16 pp
NTLA: -12.43% · AUPH: -6.27%
3M Horizon AUPH +14.93 pp
NTLA: -13.79% · AUPH: +1.14%
6M Horizon AUPH +20.4 pp
NTLA: -21.2% · AUPH: -0.8%
1Y Horizon NTLA +13.66 pp
NTLA: +15.34% · AUPH: +1.68%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue AUPH Revenue NTLA Op. Margin AUPH Op. Margin Margin Leader
FY2018 $30M $0M -298.6% -11930.9% NTLA
FY2019 $40M $0M -246.8% -28598.4% NTLA
FY2020 $60M $50M -235.5% -208.1% AUPH
FY2021 $30M $50M -810.4% -396.3% AUPH
FY2022 $50M $130M -879.0% -83.2% AUPH
FY2023 $40M $180M -1420.5% -52.2% AUPH
FY2024 $60M $240M -923.1% -2.0% AUPH
FY2025 $70M $280M -651.7% 37.1% AUPH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AUPH CONSOLIDATION
101d in phase · OBV DISTRIBUTION
Current IV 55.8%
IV Percentile 48th %ile
Put/Call OI Skew 0.12x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact AUPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
AUPH Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 51.6% operating margin.
OpEx & R&D Reinvestment 24.1% of Rev ($78M)
90D Engineering Disclosures 0 Published

Investor FAQ NTLA vs AUPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Aurinia Pharmaceuticals Inc (AUPH) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas AUPH carries 55.7/100 (HOLD) at $15.47 (13.6x Forward P/E, 51.6% operating margin). Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile AUPH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AUPH leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with AUPH at +13.9% YoY revenue growth and +0.0% YoY earnings growth on $322M TTM revenue (75.7% gross margin, 51.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while AUPH shifted +460.0%. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus 24.1% of Rev ($78M) (0 disclosures) for AUPH.

AUPH screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas AUPH trades at 13.6x Forward P/E, 7.0x Trailing P/E, N/M PEG, and 6.7x EV/Revenue (55.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus AUPH (61.4% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, AUPH carries 55.8% implied volatility (48th %ile, Balanced (25th–60th %ile)), a 0.12x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.67β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.